Loading…

Preparation and field study of combined vaccine against Clostridium perfringens type A and bovine viral diarrhea virus in camels

Purpose: The key objective of this study was to formulate a local combined inactivated gel adjuvanted vaccine containing bovine viral diarrhea virus (BVDV)-1, BVDV-2 viruses and Clostridium perfringens type A toxoid. The study evaluated its ability to enhance protective active immune response in cam...

Full description

Saved in:
Bibliographic Details
Published in:Clinical and experimental vaccine research (Seoul) 2022, Vol.11 (1), p.30-42
Main Authors: Hamed Adel Elhelw, Maha Raafat Abd el Fadeel, Elham El-Sergany, Ahmad Allam, Mohamed Karam Elbayoumy, Adel Mahrous El-Kattan, Alaa Abdel-Moneim El-kholy
Format: Article
Language:Korean
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 42
container_issue 1
container_start_page 30
container_title Clinical and experimental vaccine research (Seoul)
container_volume 11
creator Hamed Adel Elhelw
Maha Raafat Abd el Fadeel
Elham El-Sergany
Ahmad Allam
Mohamed Karam Elbayoumy
Adel Mahrous El-Kattan
Alaa Abdel-Moneim El-kholy
description Purpose: The key objective of this study was to formulate a local combined inactivated gel adjuvanted vaccine containing bovine viral diarrhea virus (BVDV)-1, BVDV-2 viruses and Clostridium perfringens type A toxoid. The study evaluated its ability to enhance protective active immune response in camels' calves against these infectious pathogens under field conditions. Materials and Methods: The local BVDV cytopathic strains and a local strain of toxigenic C. perfringens type A were used in vaccines formulation. Vaccines A and B were monovalent vaccines against C. perfringens and both strains of BVDVs, respectively. While the vaccine C was the combined vaccine used against the three agents. All vaccines were adjuvanted with Montanide gel. Sterility, safety, and potency tests were applied on the formulated vaccines. Virus neutralization and toxin anti-toxin neutralization tests were used to evaluate the immune responses. Results: Both monovalent (vaccine A) and combined vaccines (vaccine C) showed a protective level (4.5 and 3 IU/mL, respectively) against C. perfringens from the 2nd-week post-vaccination. The titer declined to 3 and 2 IU/mL, respectively at the 5th-month post-vaccination. The titer against BVDV, the monovalent vaccine (vaccine B) reached the beak (1.95 IU/mL) at the 1st-month post-vaccination and lasted till 6th-month post-vaccination (0.92 and 0.94 IU/mL) for BVDV-1a and BVDV-2, respectively. Conclusion: Vaccination of camels with the combined vaccine adjuvanted by Montanide gel containing C. perfringens type A toxoid and BVDV strains with 6-month intervals is recommended to protect camels safely and efficiently against such infections in the field.
format article
fullrecord <record><control><sourceid>kisti</sourceid><recordid>TN_cdi_kisti_ndsl_JAKO202231743297389</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>JAKO202231743297389</sourcerecordid><originalsourceid>FETCH-kisti_ndsl_JAKO2022317432973893</originalsourceid><addsrcrecordid>eNqNjEFrwkAQhRdpQWn9D3PxKJjd1OhRpKXUgz300FuYZCd2cLMbdjYBb_3pVRHPPb3vwffeSE20XhVzs1x-P9z5JRurqQhXizwvjMnybKJ-PyN1GDFx8IDeQsPkLEjq7QlCA3VoK_ZkYcC6PgPgAdlLgq0LkiJb7lvoKDaR_YG8QDp1BJvrVRWGy2LgiA4sY4w_hJfaC7CHGlty8qweG3RC01s-qdnb69f2fX5kSVx6K6782Oz2eqG1yYrc6HVhVmvzX-8Piu5Riw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Preparation and field study of combined vaccine against Clostridium perfringens type A and bovine viral diarrhea virus in camels</title><source>Open Access: PubMed Central</source><source>Publicly Available Content Database</source><creator>Hamed Adel Elhelw ; Maha Raafat Abd el Fadeel ; Elham El-Sergany ; Ahmad Allam ; Mohamed Karam Elbayoumy ; Adel Mahrous El-Kattan ; Alaa Abdel-Moneim El-kholy</creator><creatorcontrib>Hamed Adel Elhelw ; Maha Raafat Abd el Fadeel ; Elham El-Sergany ; Ahmad Allam ; Mohamed Karam Elbayoumy ; Adel Mahrous El-Kattan ; Alaa Abdel-Moneim El-kholy</creatorcontrib><description>Purpose: The key objective of this study was to formulate a local combined inactivated gel adjuvanted vaccine containing bovine viral diarrhea virus (BVDV)-1, BVDV-2 viruses and Clostridium perfringens type A toxoid. The study evaluated its ability to enhance protective active immune response in camels' calves against these infectious pathogens under field conditions. Materials and Methods: The local BVDV cytopathic strains and a local strain of toxigenic C. perfringens type A were used in vaccines formulation. Vaccines A and B were monovalent vaccines against C. perfringens and both strains of BVDVs, respectively. While the vaccine C was the combined vaccine used against the three agents. All vaccines were adjuvanted with Montanide gel. Sterility, safety, and potency tests were applied on the formulated vaccines. Virus neutralization and toxin anti-toxin neutralization tests were used to evaluate the immune responses. Results: Both monovalent (vaccine A) and combined vaccines (vaccine C) showed a protective level (4.5 and 3 IU/mL, respectively) against C. perfringens from the 2nd-week post-vaccination. The titer declined to 3 and 2 IU/mL, respectively at the 5th-month post-vaccination. The titer against BVDV, the monovalent vaccine (vaccine B) reached the beak (1.95 IU/mL) at the 1st-month post-vaccination and lasted till 6th-month post-vaccination (0.92 and 0.94 IU/mL) for BVDV-1a and BVDV-2, respectively. Conclusion: Vaccination of camels with the combined vaccine adjuvanted by Montanide gel containing C. perfringens type A toxoid and BVDV strains with 6-month intervals is recommended to protect camels safely and efficiently against such infections in the field.</description><identifier>ISSN: 2287-3651</identifier><identifier>EISSN: 2287-366X</identifier><language>kor</language><ispartof>Clinical and experimental vaccine research (Seoul), 2022, Vol.11 (1), p.30-42</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,4024</link.rule.ids></links><search><creatorcontrib>Hamed Adel Elhelw</creatorcontrib><creatorcontrib>Maha Raafat Abd el Fadeel</creatorcontrib><creatorcontrib>Elham El-Sergany</creatorcontrib><creatorcontrib>Ahmad Allam</creatorcontrib><creatorcontrib>Mohamed Karam Elbayoumy</creatorcontrib><creatorcontrib>Adel Mahrous El-Kattan</creatorcontrib><creatorcontrib>Alaa Abdel-Moneim El-kholy</creatorcontrib><title>Preparation and field study of combined vaccine against Clostridium perfringens type A and bovine viral diarrhea virus in camels</title><title>Clinical and experimental vaccine research (Seoul)</title><addtitle>Clinical and experimental vaccine research</addtitle><description>Purpose: The key objective of this study was to formulate a local combined inactivated gel adjuvanted vaccine containing bovine viral diarrhea virus (BVDV)-1, BVDV-2 viruses and Clostridium perfringens type A toxoid. The study evaluated its ability to enhance protective active immune response in camels' calves against these infectious pathogens under field conditions. Materials and Methods: The local BVDV cytopathic strains and a local strain of toxigenic C. perfringens type A were used in vaccines formulation. Vaccines A and B were monovalent vaccines against C. perfringens and both strains of BVDVs, respectively. While the vaccine C was the combined vaccine used against the three agents. All vaccines were adjuvanted with Montanide gel. Sterility, safety, and potency tests were applied on the formulated vaccines. Virus neutralization and toxin anti-toxin neutralization tests were used to evaluate the immune responses. Results: Both monovalent (vaccine A) and combined vaccines (vaccine C) showed a protective level (4.5 and 3 IU/mL, respectively) against C. perfringens from the 2nd-week post-vaccination. The titer declined to 3 and 2 IU/mL, respectively at the 5th-month post-vaccination. The titer against BVDV, the monovalent vaccine (vaccine B) reached the beak (1.95 IU/mL) at the 1st-month post-vaccination and lasted till 6th-month post-vaccination (0.92 and 0.94 IU/mL) for BVDV-1a and BVDV-2, respectively. Conclusion: Vaccination of camels with the combined vaccine adjuvanted by Montanide gel containing C. perfringens type A toxoid and BVDV strains with 6-month intervals is recommended to protect camels safely and efficiently against such infections in the field.</description><issn>2287-3651</issn><issn>2287-366X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNqNjEFrwkAQhRdpQWn9D3PxKJjd1OhRpKXUgz300FuYZCd2cLMbdjYBb_3pVRHPPb3vwffeSE20XhVzs1x-P9z5JRurqQhXizwvjMnybKJ-PyN1GDFx8IDeQsPkLEjq7QlCA3VoK_ZkYcC6PgPgAdlLgq0LkiJb7lvoKDaR_YG8QDp1BJvrVRWGy2LgiA4sY4w_hJfaC7CHGlty8qweG3RC01s-qdnb69f2fX5kSVx6K6782Oz2eqG1yYrc6HVhVmvzX-8Piu5Riw</recordid><startdate>2022</startdate><enddate>2022</enddate><creator>Hamed Adel Elhelw</creator><creator>Maha Raafat Abd el Fadeel</creator><creator>Elham El-Sergany</creator><creator>Ahmad Allam</creator><creator>Mohamed Karam Elbayoumy</creator><creator>Adel Mahrous El-Kattan</creator><creator>Alaa Abdel-Moneim El-kholy</creator><scope>JDI</scope></search><sort><creationdate>2022</creationdate><title>Preparation and field study of combined vaccine against Clostridium perfringens type A and bovine viral diarrhea virus in camels</title><author>Hamed Adel Elhelw ; Maha Raafat Abd el Fadeel ; Elham El-Sergany ; Ahmad Allam ; Mohamed Karam Elbayoumy ; Adel Mahrous El-Kattan ; Alaa Abdel-Moneim El-kholy</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-kisti_ndsl_JAKO2022317432973893</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>kor</language><creationdate>2022</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hamed Adel Elhelw</creatorcontrib><creatorcontrib>Maha Raafat Abd el Fadeel</creatorcontrib><creatorcontrib>Elham El-Sergany</creatorcontrib><creatorcontrib>Ahmad Allam</creatorcontrib><creatorcontrib>Mohamed Karam Elbayoumy</creatorcontrib><creatorcontrib>Adel Mahrous El-Kattan</creatorcontrib><creatorcontrib>Alaa Abdel-Moneim El-kholy</creatorcontrib><collection>KoreaScience</collection><jtitle>Clinical and experimental vaccine research (Seoul)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hamed Adel Elhelw</au><au>Maha Raafat Abd el Fadeel</au><au>Elham El-Sergany</au><au>Ahmad Allam</au><au>Mohamed Karam Elbayoumy</au><au>Adel Mahrous El-Kattan</au><au>Alaa Abdel-Moneim El-kholy</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Preparation and field study of combined vaccine against Clostridium perfringens type A and bovine viral diarrhea virus in camels</atitle><jtitle>Clinical and experimental vaccine research (Seoul)</jtitle><addtitle>Clinical and experimental vaccine research</addtitle><date>2022</date><risdate>2022</risdate><volume>11</volume><issue>1</issue><spage>30</spage><epage>42</epage><pages>30-42</pages><issn>2287-3651</issn><eissn>2287-366X</eissn><abstract>Purpose: The key objective of this study was to formulate a local combined inactivated gel adjuvanted vaccine containing bovine viral diarrhea virus (BVDV)-1, BVDV-2 viruses and Clostridium perfringens type A toxoid. The study evaluated its ability to enhance protective active immune response in camels' calves against these infectious pathogens under field conditions. Materials and Methods: The local BVDV cytopathic strains and a local strain of toxigenic C. perfringens type A were used in vaccines formulation. Vaccines A and B were monovalent vaccines against C. perfringens and both strains of BVDVs, respectively. While the vaccine C was the combined vaccine used against the three agents. All vaccines were adjuvanted with Montanide gel. Sterility, safety, and potency tests were applied on the formulated vaccines. Virus neutralization and toxin anti-toxin neutralization tests were used to evaluate the immune responses. Results: Both monovalent (vaccine A) and combined vaccines (vaccine C) showed a protective level (4.5 and 3 IU/mL, respectively) against C. perfringens from the 2nd-week post-vaccination. The titer declined to 3 and 2 IU/mL, respectively at the 5th-month post-vaccination. The titer against BVDV, the monovalent vaccine (vaccine B) reached the beak (1.95 IU/mL) at the 1st-month post-vaccination and lasted till 6th-month post-vaccination (0.92 and 0.94 IU/mL) for BVDV-1a and BVDV-2, respectively. Conclusion: Vaccination of camels with the combined vaccine adjuvanted by Montanide gel containing C. perfringens type A toxoid and BVDV strains with 6-month intervals is recommended to protect camels safely and efficiently against such infections in the field.</abstract><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2287-3651
ispartof Clinical and experimental vaccine research (Seoul), 2022, Vol.11 (1), p.30-42
issn 2287-3651
2287-366X
language kor
recordid cdi_kisti_ndsl_JAKO202231743297389
source Open Access: PubMed Central; Publicly Available Content Database
title Preparation and field study of combined vaccine against Clostridium perfringens type A and bovine viral diarrhea virus in camels
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T06%3A44%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-kisti&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Preparation%20and%20field%20study%20of%20combined%20vaccine%20against%20Clostridium%20perfringens%20type%20A%20and%20bovine%20viral%20diarrhea%20virus%20in%20camels&rft.jtitle=Clinical%20and%20experimental%20vaccine%20research%20(Seoul)&rft.au=Hamed%20Adel%20Elhelw&rft.date=2022&rft.volume=11&rft.issue=1&rft.spage=30&rft.epage=42&rft.pages=30-42&rft.issn=2287-3651&rft.eissn=2287-366X&rft_id=info:doi/&rft_dat=%3Ckisti%3EJAKO202231743297389%3C/kisti%3E%3Cgrp_id%3Ecdi_FETCH-kisti_ndsl_JAKO2022317432973893%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true